A disease activity guided , dose reduction strategy of adalimumab or etanercept to treat rheumatoid arthritis is non-inferior to usual care with regard to major flaring , while resulting in the successful dose reduction or stopping in two thirds of patients.Trial registration Dutch trial register ( www.trialregister.nl ) , NTR 3216 .